Assessment of the impact of different therapeutic approaches on the urobiome changes in children with recurrent urinary tract infection

Authors

  • T. V. Budnik Shupyk National Medical Academy of Postgraduate Academy, Kyiv, Ukraine, Ukraine https://orcid.org/0000-0003-3956-3903
  • L. V. Kvashnina SI «Institute of Pediatrics, Obstetrics and Gynecology named of academician O.M. Lukyanova of the NAMS of Ukraine», Kyiv, Ukraine
  • E. M. Mordovets Kyiv City Children's Clinical Hospital No. 1, Ukraine, Ukraine
  • N. O. Tikhonenko Kyiv City Children's Clinical Hospital No. 1, Ukraine, Ukraine
  • T. O. Gorokhovska Kyiv City Children's Clinical Hospital No. 1, Ukraine, Ukraine
  • O. O. Markotenko Kyiv City Children's Clinical Hospital No. 1, Ukraine, Ukraine
  • T. M. Vinogradova Kyiv City Children's Clinical Hospital No. 1, Ukraine, Ukraine

DOI:

https://doi.org/10.15574/PP.2019.79.50

Keywords:

urinary tract infection, children, urobiome, antibacterial resistance, multicomponent vaccine

Abstract

The aim is to investigate functional dynamics of urobiome in children with recurrent urinary tract infection (UTI) against the background of traditional and alternative therapy in comparison groups.
Patients and methods. A prospective, open, randomized, parallel to the design of independent groups, clinical trial was conducted during 2018–2019. The trial involved 21 girls aged 7 to 18 years old with recurrent course of UTI (at least 3–5 episodes in the last year) in the active phase of the disease. The trial participants were divided into 3 groups (7 patients each): in the 1st group, a combination of antibiotic (cephalosporin III generation) and official multivalent urological vaccine were used as basic empirical therapy; in the 2nd group — antibacterial agent (the same cephalosporin III generation as in the 1st group); in the 3rd group (patients without fever) — only urological vaccine.
The research methods include general clinical, laboratory, physical, instrumental, analytical and statistical. Statistical processing of the obtained data was performed using the STATISTICA 13 program (StatSoftInc) and MSExcel. In addition to evaluating the standard options of descriptive statistics — estimating median, mean square deviation (Ме±SD), we also solved other statistical problems for nonparametric variables: assessment of the probability of an event using the odds ratio (OR) method with a 95% confidence interval (CI), the strength of the correlation between the parameters according to the Pearson correlation criterion χ2. For all types of analysis, the differences were considered statistically significant at p <0.05 according to the Wilcoxon t-test.
Results. The efficacy of vaccine therapy without antibacterial therapy in patients with recurrent UTI who have no signs of a systemic inflammatory response has been established. The possibility of restoring the antibacterial sensitivity of resistant pathogen strains in case of multicomponent urological vaccine use in cycles of 6 months or more has been found. Standard vaccination with Urivac: 3 cycles for 3 months in a regimen of alternating 10-day use with a 20-day break. In case of medical necessity and restoration of the antibacterial sensitivity of pathogens, the course of therapy can be extended up to 6–12 months.
Conclusions. It has been shown that further applied research of alternative vaccine treatment agent will allow individualizing and reducing antibiotics use for patients with UTIs, as well as establishing mechanisms of restoring antibacterial sensitivity of microorganisms.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee participating institutions. The informed consent of the patient was obtained for conducting the studies.
No conflict of interest were declared by the authors.

References

Bondar MV, Pylypenko MM, Svintukovskyi MIu ta in. (2016). Antybiotykorezystentnist mikroorhanizmiv: mekhanizmy rozvytku y shliakhy zapobihannia. Medytsyna neotlozhnikh sostoianiy. 3 (74): 11–15.

Budnik TV. (2015). Antibiotikorezistentnost v kontekste infektsii mochevyivodyaschih putey. Semeynaya meditsina. 4 (60): 78–85.

Budnik TV. (2019). Pytannia ratsionalnoho vykorystannia antybiotykiv v likuvanni infektsii sechovykh shliakhiv ta stratehiia upravlinnia antybiotykorezystentnistiu. Semeynaya meditsina. 1 (81): 1–5.

Zaytsev AV, Tupikina NV. (2014). Retsidiviruyuschaya infektsiya mochevyih putey – mezhdistsiplinarnaya problema. Meditsinskiy sovet: 36–44.

Ivanov DD, Kushnirenko SV. (2009). Lechenie tsistita s pozitsiy dokazatelnoy meditsinyi. Ukrainskyi terapevtychnyi zhurnal. 1: 30–32.

Ivanov DD, Kushnirenko SV. (2015). Infektsii sechovykh shliakhiv u praktytsi simeinoho likaria. Semeynaya meditsina. 2 (58): 46–50.

Kriuchko TO, Kuzmenko NV, Kharshman VP, Koziar NH. (2019). Retsydyvuiuchyi tsystyt u ditei: rezervy profilaktyky Semeynaya meditsina. 2 (82): 43–48.

Palagin IS i dr. (2012). Sovremennoe sostoyanie antibiotikorezistentnosti vozbuditeley vnebolnichnyih infektsiy mochevyih putey v Rossii: rezultatyi issledovaniya «DARMIS» (2010-2011). Klin. mikrobiol. antimikrob. himioter. 14; 4: 280–303.

Perepanova TS, Kozlov RS i dr. (2012). Empiricheskiy vyibor antimikrobnyih preparatov pri neoslozhnennoy infektsii nizhnih mochevyih putey: issledovanie rezistentnosti vozbuditeley «DARMIS». Eksperimentalnaya i klinicheskaya urologiya. 2: 78-83.

Suhorukova MV, Eydelshteyn MV, Skleenova EYu i dr. (2014). Antibiotikorezistentnost nozokomialnyih shtammov Enterobacteriaceae v statsionarah Rossii: rezultatyi mnogotsentrovogo epidemiologicheskogo issledovaniya MARAFON v 2011-2012 gg. Klinicheskaya mikrobiologiya i antimikrobnaya himioterapiya. 16; 4: 254-265.

Angelini KJ. (2017, Mar-Apr). An Integrative Review of Current Research on the Role of the Female Urinary Microbiota in Overactive Bladder Symptoms. Urol Nurs. 37 (2): 94–100. https://doi.org/10.7257/1053-816X.2017.37.2.94

Aragon IM, Herrera-Imbroda B, Queipo-Ortuno MI, Castillo E, Del Moral JS, Gomez-Millan J, Yucel G, Lara MF. (2018, Jan). The Urinary Tract Microbiome in Health and Disease. Eur Urol Focus. 4 (1): 128–138. https://doi.org/10.1016/j.euf.2016.11.001; PMid:28753805

Clinical & Laboratory Standards Institute: CLSI Guidelines. Retrieved from http: https://clsi.org.

European Association of Urology. (2015). Guidelines on urological infections.

Flores-Mireles AL, Walker JN, Caparon M, Scott J. Hultgren. (2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature Reviews Microbiology. 13: 269–284. https://doi.org/10.1038/nrmicro3432; PMid:25853778 PMCid:PMC4457377

Hiergeist A, Gessner A. (2017, Mar). Clinical implications of the microbiome in urinary tract diseases. Curr Opin Urol. 27 (2): 93–98. https://doi.org/10.1097/MOU.0000000000000367; PMid:27898455

Kline KA, Lewis AL. (2016, Apr). Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary Tract. Microbiol Spectr: 4 (2): 27–40. https://doi.org/10.1128/microbiolspec.UTI-0012-2012; PMid:27227294 PMCid:PMC4888879

Magistro G, Stief CG (2019, Jan). The Urinary Tract Microbiome: The Answer to All Our Open Questions. Eur Urol Focus. 5 (1): 36–38. https://doi.org/10.1016/j.euf.2018.06.011; PMid:30042043

Schneeweiss J, Koch M, Umek W. (2016, Sep). The human urinary microbiome and how it relates to urogynecology. Int Urogynecol J. 27 (9): 1307–1312. https://doi.org/10.1007/s00192-016-2944-5; PMid:26811114

Tina Gao, Kymora B. Scotland (2019). The Role of Bacteria in Urology (Bacteria in the Genitourinary Tract: The Microbiota and Efforts to Address Infection). Springer Nature Switzerland AG: 193: 1–6. https://doi.org/10.1007/978-3-030-17542-9_1

Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. (2015, Feb). The microbiome of the urinary tract – a role beyond infection. Nat Rev Urol. 12 (2): 81–90. https://doi.org/10.1038/nrurol.2014.361; PMid:25600098

Wolfe AJ, Brubaker L Nat Rev Urol. (2019, Feb). Urobiome updates advances in urinary microbiome research. 16 (2): 73–74. https://doi.org/10.1038/s41585-018-0127-5; PMid:30510275 PMCid:PMC6628711